Post-Traumatic Stress Disorder

What it is

PTSD is a psychiatric disorder that can develop after exposure to a traumatic event including combat, sexual assault, serious accident, natural disaster, or violence. Core symptom clusters defined in DSM-5 include:

• Intrusion symptoms: recurrent involuntary memories, distressing dreams, flashbacks, intense psychological or physiological reactions to trauma cues.
• Avoidance: persistent effort to avoid trauma-related thoughts, feelings, conversations, places, or people.
• Negative alterations in cognition and mood: persistent negative beliefs about self or world, persistent negative emotional state, diminished interest, detachment, inability to experience positive emotions.
• Alterations in arousal and reactivity: hypervigilance, exaggerated startle response, irritability, reckless behavior, sleep disturbance, difficulty concentrating.

Symptoms persist for more than one month and cause significant distress or functional impairment. PTSD has elevated prevalence in combat veterans (~12-30% in Iraq/Afghanistan-era veterans), sexual assault survivors, first responders, and refugees.

Cannabis and cannabis-derived therapies

Many state medical cannabis programs include PTSD as a qualifying condition, with patient enrollment for PTSD particularly high among military veterans. The clinical evidence base is more limited than for chronic pain or chemotherapy-induced nausea.

Evidence summary

The 2017 NASEM consensus report classified the evidence as limited, citing one randomized trial of the synthetic cannabinoid nabilone for sleep symptoms (Jetly et al., 2015, Canadian military personnel). The 2024 NASEM update did not move PTSD to a higher evidence tier; subsequent randomized trials remain sparse.

Notable post-2017 evidence:

• MAPS Phase 2 trial of smoked cannabis (2021): 76-participant placebo-controlled trial in veterans found no statistically significant difference between high-THC, high-CBD, balanced THC/CBD, and placebo on PTSD symptom severity (CAPS-5).
• Observational studies: consistent patient-reported benefit for sleep, nightmares, hyperarousal, and anxiety. Reduced opioid co-use reported in some cohorts.
• Nightmare-focused evidence: several small trials and case series support nabilone for reduction of trauma-related nightmares; mechanism may involve REM sleep modulation.

Symptom-specific picture

The strongest patient-reported and most consistent trial-evidence findings are for sleep and nightmare reduction. Broader PTSD symptom remission is not supported by current trial data.

• Sleep: moderate evidence; nabilone effect on nightmares replicated in multiple small studies.
• Anxiety: mixed; THC has biphasic dose-response (lower doses anxiolytic, higher doses anxiogenic).
• Hyperarousal: patient-reported benefit, limited trial evidence.
• Intrusive memories / flashbacks: insufficient evidence for or against.
• Avoidance: cannabis can paradoxically reinforce avoidance patterns; this is a documented concern in trauma-focused therapy contexts.

Endocannabinoid pharmacology in PTSD

PTSD is associated with altered endocannabinoid signaling. PTSD patients show lower circulating anandamide levels and higher CB1 receptor availability in pain- and fear-processing brain regions (PET imaging studies). This has motivated interest in cannabinoid pharmacotherapy, though replacement of deficient endogenous signaling with exogenous THC has not produced consistent symptomatic benefit in controlled trials.

The endocannabinoid system is also active in fear extinction (the therapeutic process targeted by trauma-focused psychotherapy). Animal models suggest CB1 activation may enhance fear extinction in low doses but impair it at high doses. This mechanism is the basis for ongoing trials of CBD as adjunct to prolonged exposure therapy.

VA / DoD position

The 2023 VA/DoD Clinical Practice Guideline for PTSD reviewed the available evidence and concluded that current data are insufficient to recommend for or against cannabis as PTSD therapy. The VA's evidence-based first-line treatments remain trauma-focused psychotherapies (Prolonged Exposure, Cognitive Processing Therapy, EMDR) and SSRIs/SNRIs (sertraline, paroxetine, venlafaxine).

VA policy explicitly permits veterans to disclose state-legal cannabis use without losing other VA benefits or care. VA providers cannot recommend cannabis (the federal Schedule I designation precludes it) but can document, monitor, and coordinate around patient cannabis use.

Federal employment and clearance considerations

PTSD is a high-prevalence condition in populations that disproportionately hold federal employment, military service, or security clearances (veterans, law enforcement, fire/EMS, federal contractors). State-legal medical cannabis use creates federal-law exposure for these populations:

• Active-duty military: UCMJ Article 112a prohibits cannabis use regardless of state law. Positive THC test results in discipline.
• Federal civilian employees: subject to federal drug-free workplace rules. Positive THC test is grounds for adverse action.
• Security clearance holders: SEAD 4 (Security Executive Agent Directive) treats current cannabis use as a security-clearance concern regardless of state legality. Past use may be mitigated by demonstrated cessation and time elapsed.
• Federal contractors: drug-free workplace requirements often extend to state-legal cannabis use.
• CDL holders: DOT testing rules prohibit cannabis use; positive test is disqualifying.

Patients in these populations should consult appropriate counsel before initiating medical cannabis for PTSD.

Risks specific to PTSD population

Several risks deserve specific attention in PTSD patients:

• Cannabis use disorder: elevated rates in PTSD population (some estimates 2-3× general adult rate). Trauma-exposed individuals are at elevated risk for substance use disorders generally.
• Experiential avoidance: cannabis can become a behavioral avoidance strategy that interferes with trauma-focused psychotherapy. Patients in active PE or CPT may need to coordinate cannabis use with the therapeutic protocol.
• Anxiety exacerbation: high-THC strains and concentrates can precipitate panic attacks in some patients, particularly THC-naive users. Lower-THC, higher-CBD formulations are commonly preferred.
• Sleep displacement: while cannabis improves sleep onset and reduces nightmare frequency, chronic use suppresses REM sleep. Discontinuation can cause REM rebound with intensified nightmares.
• Co-occurring TBI: veterans with combined PTSD + TBI face additive cognitive and emotional risks; cannabis effects on cognition can compound TBI-related deficits.

Practical guidance

Cannabis should be considered an adjunct to evidence-based PTSD treatment (psychotherapy + pharmacotherapy), not a substitute. Patients should coordinate cannabis use with their mental-health provider, particularly when actively in trauma-focused therapy. Sleep-focused use (low-dose evening administration) has the most consistent evidence base. Patients should monitor for use-pattern escalation, increasing anxiety, or interference with psychotherapy.

Related conditions

PTSD frequently co-occurs with chronic-pain (particularly in veterans), traumatic-brain-injury, anxiety-disorders, opioid-use-disorder, and sleep disorders. The mmjnow library covers each of these as separate conditions with overlapping clinical considerations.